Weight & metabolic
Retatrutide
Triple GLP-1/GIP/Glucagon Agonist
The most anticipated next-generation weight management peptide. Activates three hormone receptors simultaneously — GLP-1, GIP, and glucagon — for the most powerful metabolic impact seen in trials to date.
Also known as: LY3437943, triple-G, triple agonist, Reta
- Status
- Retatrutide is in Phase 3 clinical trials and not approved.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- ~6 days (estimated)
- How it's taken
- Weekly subcutaneous injection
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1, GIP, Glucagon
How Retatrutide works
Unlike single or dual-action peptides, Retatrutide hits three targets at once. GLP-1 reduces appetite and slows digestion, GIP enhances insulin response and fat metabolism, and glucagon receptor activation increases energy expenditure and fat burning in the liver.
What research has looked at
- Up to 28.7% weight loss shown in Phase 2 trials (TRIUMPH)
- Triple-action mechanism — most comprehensive approach
- Significant reduction in liver fat
- Improved metabolic markers across the board
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea and vomiting (dose-dependent)
- Diarrhea
- Constipation
- Decreased appetite
- Injection site reactions
- Long-term safety still being evaluated
Sources
- Active clinical trials for retatrutide · U.S. National Library of Medicine
- PubMed research on retatrutide triple agonist obesity · NIH · National Library of Medicine
- DrugBank record for retatrutide · DrugBank
Track Retatrutide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Retatrutide FAQ
What is Retatrutide?
The most anticipated next-generation weight management peptide. Activates three hormone receptors simultaneously — GLP-1, GIP, and glucagon — for the most powerful metabolic impact seen in trials to date.
How does Retatrutide work?
Unlike single or dual-action peptides, Retatrutide hits three targets at once. GLP-1 reduces appetite and slows digestion, GIP enhances insulin response and fat metabolism, and glucagon receptor activation increases energy expenditure and fat burning in the liver.
Is Retatrutide FDA approved?
No. Retatrutide is in Phase 3 clinical trials and not approved. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Retatrutide?
Reported half-life: ~6 days (estimated).
How is Retatrutide taken?
Weekly subcutaneous injection.
What side effects have been reported with Retatrutide?
Reported in the sources: Nausea and vomiting (dose-dependent); Diarrhea; Constipation; Decreased appetite; Injection site reactions; Long-term safety still being evaluated.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.